Efficacy of astragalus combined with renin-angiotensin-aldosterone system blockers in the treatment of stage III diabetic nephropathy: a systematic review and meta-analysis

被引：3

作者：

Lin, Yu-qiong ^{[1
]}

Yu, Feng ^{[2
]}

Chen, Hui-jun ^{[3
]}

Deng, Yuan-rong ^{[1
]}

Lin, Jin ^{[1
]}

Xu, Ying ^{[1
]}

Zheng, Xin ^{[1
]}

Zhang, Jing-wen ^{[1
]}

Liu, Jun-feng ^{[1
]}

机构：

[1] Fujian Hlth Coll, Dept Med, 366 Jingxi Town, Fuzhou, Fujian, Peoples R China

[2] Fujian Med Univ, Dept Infect, Union Hosp, Fuzhou, Fujian, Peoples R China

[3] Fujian Univ Tradit Chinese Med, Dept Urol, Affiliated Hosp 2, Fuzhou, Fujian, Peoples R China

来源：

RENAL FAILURE | 2024年 / 46卷 / 02期

关键词：

Astragalus; RAAS blockers; diabetic nephropathy; meta-analysis; KIDNEY-DISEASE;

D O I：

10.1080/0886022X.2024.2359033

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: To determine the efficacy and safety of Astragalus combined with renin-angiotensin-aldosterone system (RAAS) blockers in treating stage III diabetic nephropathy (DN) by meta-analysis. Methods: PubMed, Embase, Cochrane Library, Wiley, and Web of Science databases were searched for articles published between August 2007 and August 2022. Clinical studies on Astragalus combined with RAAS blockers for the treatment of stage III DN were included. Meta-analysis was performed by RevMan 5.1 and Stata 14.3 software. Results: A total of 32 papers were included in this meta-analysis, containing 2462 patients from randomized controlled trials, with 1244 receiving the combination treatment and 1218 solely receiving RAAS blockers. Astragalus combined with RAAS blockers yielded a significantly higher total effective rate (TER) (mean difference [MD] 3.63, 95% confidence interval [CI] 2.59-5.09) and significantly reduced urinary protein excretion rate (UPER), serum creatinine (Scr), blood urine nitrogen (BUN) and glycosylated hemoglobin (HbAlc) levels. In subgroup analysis, combining astragalus and angiotensin receptor blocker significantly lowered fasting plasma glucose (FPG) and 24 h urinary protein (24hUTP) levels, compared with the combined astragalus and angiotensin-converting enzyme inhibitor treatment. Meanwhile, the latter significantly decreased the urinary microprotein (beta(2)-MG). Importantly, the sensitivity analysis confirmed the study's stability, and publication bias was not detected for UPER, BUN, HbAlc, FPG, or beta(2)-MG. However, the TER, SCr, and 24hUTP results suggested possible publication bias. Conclusions: The astragalus-RAAS blocker combination treatment is safe and improves outcomes; however, rigorous randomized, large-scale, multi-center, double-blind trials are needed to evaluate its efficacy and safety in stage III DN.

引用

页数：12

共 53 条

[1] A review of traditional Chinese medicine on treatment of diabetic retinopathy and involved mechanisms [J].

Ai, Xiaopeng ;

Yu, Peiling ;

Hou, Ya ;

Song, Xinchen ;

Luo, Jie ;

Li, Ning ;

Lai, Xianrong ;

Wang, Xiaobo ;

Meng, Xianli .

BIOMEDICINE & PHARMACOTHERAPY, 2020, 132

[2] Systems for grading the quality of evidence and the strength of recommendations -: I:: Critical appraisal of existing approaches The GRADE Working Group -: art. no. 38 [J].

Atkins, D ;

Eccles, M ;

Flottorp, S ;

Guyatt, GH ;

Henry, D ;

Hill, S ;

Liberati, A ;

O'Connell, D ;

Oxman, AD ;

Phillips, B ;

Schünemann, H ;

Edejer, TTT ;

Vist, GE ;

Williams, JW .

BMC HEALTH SERVICES RESEARCH, 2004, 4 (1)

[3]

Bs C., 2009, J Clin Exp Med, V8, P2

[4]

C C., 2010, Mod J Integr Trad Chin West Med, V19, P2

[5]

Cai R., 2016, Mod J Integr Trad Chin West Med, V25, P3

[6]

Chen JN., 2010, Chin Community Doctors, V12, P1

[7]

Chen JP., 2022, Pract Clin J Integr Trad Chin West Med, V22, P4

[8]

Chen JY., 2022, Chin J Gerontol, V42, P7

[9]

Cui B., 2011, Chin J Integr Trad West Nephrol, V12, P2

[10]

Fang LY., 2018, J Nanjing Univ Trad Chin Med, V34, P4

← 1 2 3 4 5 6 →